We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HDL‐C Levels Associated with Harmful CKD Progression

By LabMedica International staff writers
Posted on 17 Apr 2019
Print article
Image: A blood test for high‐density lipoprotein that may indicate adverse renal outcomes for patients with chronic kidney disease (Photo courtesy of Drs. Wolfson).
Image: A blood test for high‐density lipoprotein that may indicate adverse renal outcomes for patients with chronic kidney disease (Photo courtesy of Drs. Wolfson).
Serum high‐density lipoprotein (HDL) has traditionally been considered to be protective against cardiovascular disease in the general population. HDL exerts an antiatherogenic effect through reverse cholesterol transport, a multiorgan process that removes excess cholesterol from lipid‐laden macrophages and peripheral tissue.

Chronic kidney disease (CKD) has become a serious health concern worldwide, given the high burden of cardiovascular events and death in patients with this condition. Dyslipidemia is common in patients with CKD and is characterized by lower levels of HDL‐C and higher levels of triglyceride and oxidized low‐density lipoprotein cholesterol.

A team of scientists at Yonsei University (Seoul, South Korea) carried out a prospective nationwide cohort study investigating various clinical courses and risk factors for the progression of CKD in Korean patients. Patients, aged between 20 and 75 years, with CKD stages from 1 to 5 before dialysis, who voluntarily provided informed consent, were enrolled from nine tertiary‐care general hospitals throughout Korea between June 2011 and February 2016. There were 2,168 patients were included in the final analysis.

After overnight fasting, blood samples were collected for measurements of creatinine. Other biochemical analyses, including lipid profiles, were done at the local laboratory of each participating center. Most laboratory parameters were measured every six months in the first year and annually thereafter, including complete blood cell count, fasting glucose, blood urea nitrogen, creatinine, albumin, calcium, and phosphorus. C‐reactive protein, iron profiles (including total iron‐binding capacity and serum ferritin), and lipid profiles (including triglyceride, HDL‐C, and low‐density lipoprotein cholesterol) were measured repeatedly after one year and biennially thereafter. The team used a creatinine method that requires calibration traceable to isotope dilution mass spectrometry, and estimated glomerular filtration rate (eGFR) was calculated using the CKD. Urine samples were analyzed for proteinuria measurement. Urine albumin/creatinine ratio was calculated as the urine albumin concentration divided by the urine creatinine concentration (mg/g).

The team reported that the primary outcome was the composite of a 50% decline in eGFR from baseline or end‐stage renal disease. The secondary outcome was the onset of end‐stage renal disease. During a median follow‐up of 3.1 years, the primary outcome occurred in 335 patients (15.5%). In a fully adjusted Cox model, the lowest category with HDL‐C of <30 mg/dL (hazard ratio, 2.21) and the highest category with HDL‐C of ≥60 mg/dL (hazard ratio, 2.05) were associated with a significantly higher risk of the composite renal outcome, compared with the reference category with HDL‐C of 50 to 59 mg/dL. This association remained unaltered in a time‐varying Cox analysis. Furthermore, consistent findings were obtained in a secondary outcome analysis for the development of end‐stage renal disease.

The authors concluded that an U‐shaped association was observed between serum HDL‐C levels and adverse renal outcomes in this large cohort of patients with CKD. The findings suggest that both low and high serum HDL‐C levels may be detrimental to patients with non-dialysis CKD. The study was published on March 12, 2019, in the Journal of the American Heart Association.

Related Links:
Yonsei University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.